Premium
Expression of the human germinal‐centre‐associated lymphoma protein in diffuse large B‐cell lymphomas in patients with rheumatoid arthritis
Author(s) -
Baecklund Eva,
Natkunam Yasodha,
Backlin Carin,
Iliadou Anastasia,
Askling Johan,
Ekbom Anders,
Feltelius Nils,
Klareskog Lars,
Enblad Gunilla,
Lossos Izidore S.,
Levy Ronald,
Sundström Christer,
Rosenquist Richard
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07011.x
Subject(s) - bcl6 , diffuse large b cell lymphoma , germinal center , lymphoma , rheumatoid arthritis , irf4 , medicine , pathology , pathogenesis , cancer research , b cell , biology , immunology , antibody , gene , biochemistry , transcription factor
Summary Diffuse large B‐cell lymphomas (DLBCL) can be subdivided into germinal centre (GC)‐like and non‐GC‐like subtypes by CD10, BCL6 and MUM1/IRF4 status. We previously reported that patients with severe rheumatoid arthritis (RA) are at increased risk of non‐GC DLBCL. This study examined a new GC‐marker, human germinal‐centre‐associated lymphoma (HGAL) protein, in RA‐DLBCL. Of 111, 38 (34%) DLBCL were HGAL‐positive and showed less disseminated disease and a tendency toward improved overall survival compared to HGAL‐negative cases. This supports that a majority of RA‐DLBCL are of non‐GC origin, indicating a specific role for activated peripheral B cells in the pathogenesis of RA‐DLBCL.